Related Experiment Videos

[Dynamic changes in hepatic myofibroblast of rabbits with Schistosoma japonicum]

Y Yang1, W Cai, G Jin

  • 1Institute of Infectious Diseases, Zhejiang Medical University, Hangzhou 310003.

Zhonghua Yi Xue Za Zhi
|November 22, 2001
PubMed
Abstract

Insights

Hepatic myofibroblasts are crucial in schistosomal hepatic fibrosis development. Interferon-gamma treatment improved fibrosis and alpha-smooth muscle actin expression in infected rabbits.

Area of Science:

  • Hepatology
  • Parasitology
  • Immunology

Context:

  • Schistosomiasis japonica causes significant liver damage and fibrosis.
  • Hepatic fibrosis is a complex process involving myofibroblast activation.
  • Understanding the dynamic changes in hepatic myofibroblasts is key to developing treatments.

Purpose:

  • To observe dynamic changes in hepatic myofibroblasts during schistosomal hepatic fibrosis.
  • To investigate the pathogenesis of hepatic fibrosis induced by Schistosoma japonicum.
  • To evaluate the efficacy of interferon-gamma in treating established fibrosis.

Summary:

  • Granulomas formed by week 6, peaking at week 8, then shrinking, while fibrosis and alpha-smooth muscle actin (SMA) positive cells progressively increased.
  • Alpha-SMA positive cells, indicative of myofibroblasts, were detected by week 4 and increased over time.
  • Interferon-gamma treatment, combined with praziquantel, significantly reduced fibrosis and alpha-SMA expression compared to saline controls, showing the best therapeutic outcome.

Impact:

  • This study highlights the critical role of myofibroblasts in the pathogenesis of schistosomal hepatic fibrosis.
  • The findings suggest that targeting myofibroblasts could be a viable therapeutic strategy for liver fibrosis.
  • Interferon-gamma demonstrates potential as an adjunct therapy for schistosomiasis-induced liver fibrosis.

Related Concept Videos